Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains

Journal of Neuroimmunology

Volumn 200, Issue 1-2, 2008, Pages 133-141

  Zisimopoulou, Paraskevi ^a   Lagoumintzis, George ^b   Poulas, Konstantinos ^b   Tzartos, Socrates J ^a,b  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Acetylcholine receptor autoantibodies; Apheresis; Extracellular domains; Immunoadsorption; Myasthenia gravis; Therapy

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; NICOTINIC RECEPTOR; RECOMBINANT PROTEIN; SEPHAROSE;

APHERESIS; ARTICLE; ESCHERICHIA COLI; IMMUNOADSORPTION; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NUCLEOTIDE SEQUENCE; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN IMMOBILIZATION;

AUTOANTIBODIES; BLOOD COMPONENT REMOVAL; ESCHERICHIA COLI; HUMANS; MYASTHENIA GRAVIS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, NICOTINIC; TIME FACTORS;

EID: 49849097621     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.06.002     Document Type: Article

References (43)

1. Batocchi A.P., Evoli A., Di Schino C., and Tonali P. Therapeutic apheresis in myasthenia gravis. Ther. Apher. 4 (2000) 275-279
2. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 (2006) 2843-2854
3. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. Jama 291 (2004) 2367-2375
4. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
5. Drachman D.B., Fambrough D.M., and Satyamurti S. Reduced acetylcholine receptors in myasthenia gravis. Trans. Am. Neurol. Ass. 98 (1973) 93-95
6. Fambrough D.M., Drachman D.B., and Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 182 (1973) 293-295
7. Fostieri E., Kostelidou K., Poulas K., and Tzartos S.J. Recent advances in the understanding and therapy of myasthenia gravis. Future Neurol. 1 (2006) 799-801
8. Guo C.Y., Li Z.Y., Xu M.Q., and Yuan J.M. Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum. J. Immunol. Methods 303 (2005) 142-147
9. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
10. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat. Rev. Neurosci. 3 (2002) 102-114
11. Keesey J.C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29 (2004) 484-505
12. Kostelidou K., Trakas N., Zouridakis M., Bitzopoulou K., Sotiriadis A., Gavra I., and Tzartos S.J. Expression and characterization of soluble forms of the extracellular domains of the beta, gamma and epsilon subunits of the human muscle acetylcholine receptor. FEBS J. 273 (2006) 3557-3568
13. Kostelidou K., Trakas N., and Tzartos S.J. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency. J. Neuroimmunol. (2007)
14. Kuks J.B., and Skallebaek D. Plasmapheresis in myasthenia gravis. A survey. Transfus. Sci. 19 (1998) 129-136
15. Kuks J.B., Limburg P.C., Horst G., Dijksterhuis J., and Oosterhuis H.J. Antibodies to skeletal muscle in myasthenia gravis. Part 1. Diagnostic value for the detection of thymoma. J. Neurol. Sci. 119 (1993) 183-188
16. Le Novere N., Corringer P.J., and Changeux J.P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J. Neurobiol. 53 (2002) 447-456
17. Lindstrom J. Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome. Annu. Rev. Immunol. 3 (1985) 109-131
18. Lindstrom J., Campbell M., and Nave B. Specificities of antibodies to acetylcholine receptors. Muscle Nerve 1 (1978) 140-145
19. Lindstrom J., Einarson B., and Tzartos S. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74 Pt C (1981) 432-460
20. Lindstrom J.M. Acetylcholine receptors and myasthenia. Muscle Nerve 23 (2000) 453-477
21. Lindstrom J.M., Engel A.G., Seybold M.E., Lennon V.A., and Lambert E.H. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J. Exp. Med. 144 (1976) 739-753
22. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 26 (1976) 1054-1059
23. Loutrari H., Tzartos S.J., and Claudio T. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the alpha subunit in myasthenia gravis antisera. Eur. J. Immunol. 22 (1992) 2949-2956
24. Massey J.M. Acquired myasthenia gravis. Neurol. Clin. 15 (1997) 577-595
25. Newsom-Davis J., Wilson S.G., Vincent A., and Ward C.D. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1 (1979) 464-468
26. Patrick J., and Lindstrom J. Autoimmune response to acetylcholine receptor. Science 180 (1973) 871-872
27. Poulas K., Tsibri E., Kokla A., Papanastasiou D., Tsouloufis T., Marinou M., Tsantili P., Papapetropoulos T., and Tzartos S.J. Epidemiology of seropositive myasthenia gravis in Greece. J. Neurol. Neurosurg. Psychiatry 71 (2001) 352-356
28. Psaridi-Linardaki L., Mamalaki A., Remoundos M., and Tzartos S.J. Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alpha-bungarotoxin binding. J. Biol. Chem. 277 (2002) 26980-26986
29. Psaridi-Linardaki L., Mamalaki A., and Tzartos S.J. Future therapeutic strategies in autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 998 (2003) 539-548
30. Psaridi-Linardaki L., Trakas N., Mamalaki A., and Tzartos S.J. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy. J. Neuroimmunol. 159 (2005) 183-191
31. Richman D.P., and Agius M.A. Treatment of autoimmune myasthenia gravis. Neurology 61 (2003) 1652-1661
32. Robertson N.P., Deans J., and Compston D.A. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J. Neurol. Neurosurg. Psychiatry 65 (1998) 492-496
33. Romi F., Skeie G.O., Aarli J.A., and Gilhus N.E. Muscle autoantibodies in subgroups of myasthenia gravis patients. J. Neurol. 247 (2000) 369-375
34. Sideris S., Lagoumintzis G., Kordas G., Kostelidou K., Sotiriadis A., Poulas K., and Tzartos S.J. Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture. J. Neuroimmunol. 189 (2007) 111-117
35. Sieb J.P. Myasthenia gravis: emerging new therapy options. Curr. Opin. Pharmacol. 5 (2005) 303-307
36. Skeie G.O., Apostolski S., Evoli A., Gilhus N.E., Hart I.K., Harms L., Hilton-Jones D., Melms A., Verschuuren J., and Horge H.W. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 13 (2006) 691-699
37. Takamori M., and Maruta T. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. Ther. Apher. 5 (2001) 340-350
38. Tsouloufis T., Mamalaki A., Remoundos M., and Tzartos S.J. Reconstitution of conformationally dependent epitopes on the N-terminal extracellular domain of the human muscle acetylcholine receptor alpha subunit expressed in Escherichia coli: implications for myasthenia gravis therapeutic approaches. Int. Immunol. 12 (2000) 1255-1265
39. Tzartos S.J., Seybold M.E., and Lindstrom J.M. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 188-192
40. Tzartos S.J., Barkas T., Cung M.T., Mamalaki A., Marraud M., Orlewski P., Papanastasiou D., Sakarellos C., Sakarellos-Daitsiotis M., Tsantili P., and Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163 (1998) 89-120
41. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J. Mol. Biol. 346 (2005) 967-989
42. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2 (2002) 797-804
43. Vincent A., Palace J., and Hilton-Jones D. Myasthenia gravis. Lancet 357 (2001) 2122-2128